Pharmacovigilance World Conference 2020 (London, United Kingdom – June 3-4, 2020)

Dublin, Feb. 12, 2020 (GLOBE NEWSWIRE) — The “Pharmacovigilance World 2020” conference has been added to ResearchAndMarkets.com’s offering.With the augmented incidence of diseases, and the non-medical use of prescription drugs, the incidence of drug abuse has increased enormously in the recent years, which is apparent with the excess documentation of adversities and drug toxicities.In this context, the drug safety and pharmacovigilance has emerged as a dynamic clinical and scientific discipline to provide adequate information and ensure health safety by the joint interaction of doctors and patients in choosing appropriate treatment method and drug. However, evidences suggest though avoidable, the adverse drug reactions (ADRs) to medicines continue to be the bigger life risk.In England, ADR was responsible for up to 6% of hospital admissions, carrying a mortality of 2% and costing the NHS 466 million per annum (654 million, US$ 602 million) in 2004. In some countries, ADR is ranked among the top 10 leading cause of mortality. The concept of drug safety and pharmacovigilance has evolved considerably and is highly necessary to keep the severity of ADR under check. In order to prevent or to reduce harm to patients and improve public health, it is vital to develop and practice mechanisms for evaluating and monitoring the safety of medicines in clinical use. Pharmacovigilance brief the potential implications of such trends on the evolution of the science.Pharmacovigilance and globalizationWomen and child health care medicines and pharmacovigilancePatient-centric approaches in PVPharmacovigilance legislation and regulationsHarmonization and pharmacovigilanceAdvanced therapeutic techniques and pharmacovigilancePharmacovigilance and data management and eudravigilancePost-marketing surveillance in pharmacovigilancePV regulations and challengesBenefit-risk management strategiesRisk management and minimizationAdverse drug reactions reportingSignal detection and post-authorization safetyGood Pharmacovigilance PracticesInnovative approaches to drug safetyStrategies to improve PVReal-World Evidence in PVBig data and AI in pharmacovigilancePharmacovigilance Monitoring and automation in Social mediaOther emerging technologies in PVAgenda
DAY 1Pharmacovigilance – significance, scope and challengesPersonalized medicinesSafe drug use: Adverse drug reactions, Adverse-drug interactions, monitoring10:00 – An Integrated care: Effective Implementation of vigilances systemsSeparated vigilance systems can lead to the emergence of divergence in terms, definitions, variety of reporting forms and methods and the build of specific databases where cross analysis is no more possible.To be more proactive and innovative in PV and to ensure that emerging problems are promptly recognized and solutions are effectively communicatedThis integrated approach is very useful, especially for emerging countries to strengthen regulatory processes and to promote high standards of product vigilance for the protection of the health and safety of Citizens.10:30 – Morning Coffee/Tea & NetworkingSales, information and knowledge of consumersAwareness, generic names, reduction of medication errors in private clinicsIndustrial associationInspection, Quality & ComplianceQuality system within organizationsCritical PV processTrainingRisk management12:20 – GxP inspections of PV system, scope, trends and challengesAdvanced therapeutic techniques and pharmacovigilanceChallenges related with monitoring and safetyBenefit-risk assessment of ATMP14:30 – Major developments in regulatory frameworkThe future of gene therapy, stem-cell therapy, and tissue engineeringEU guidelines and updates – Good Manufacturing Practices for ATMPs15:00 – Afternoon Tea/CoffeeAll attendees will have a great opportunity to discuss a selection of the most interesting topics addressed during the conference in small groups with their peers.Every table will nominate a head of the table, who will summarize the topic discussed, present the main puzzles and questions posed.Strategies and OutsourcingEconomyPV Quality assurancepost-authorization safety studiesBuilding partnershipsIdentifying the key areas for outsourcingThe main challenges faced and impact of new legislationCore competencies, activities-database, follow-up studies, case-studies, etc.16:50 – Chairperson’s closing remarksPSMF summary design, role of QPPV and managing auditsResponsibilities of stakeholders.Accessibility of PSMF and Transparency and ensuring complianceChallenges in the managing data collection, audit information and documenting changes in logbooks, transferring information to license partners or third parties.10:00 – Eudravigilance – how well has it been integrated and accepted by organizationsImprovement in data analysis and exchange of individual case safety reports (ICSRs) between EMA, and various parties.The new and improved of EudravigilanceConnecting EMA with other regulatory bodies using Eudravigilance10:30 – Morning Coffee/Tea & DiscussionLimitations of premarketing clinical trialsAdhering to various national and international regulatory bodiesAdverse event reports, role of FDA/ CDER/ DPV/ FDA Adverse Event Reporting System (FAERS)Type of post-marketing surveillance – Role of MedWatch or similarAdverse Event Reporting and Signal DetectionPresent Drug safety signal detection systems and tools and what do they lackEmerging techniques and tools in the detection and management of signalsSources for identifying safety signals12:50 – Networking & LuncheonAssessment with comprehensive data qualityCompliant safety system (GxP compliant, inspection-ready system)Safety signals, effective trials, strategic risk assessment decisions14:00 – Minimizing risk and innovative approaches for prediction such as the use of safety biomarkers and pharmacogeneticsEver expanding data and its safetyImportance and application of AIImproving speed, accuracy and reliability using AI15:50 – Real-World Evidence for Assessing Drug SafetyRole of internet/ communication techniques, advertisementIllegal effectsPost-market surveillance of devicesTherapeutic good administrationSafety management16:50 – Panel Discussion: Innovation and the future of PharmacovigilanceImportance of bringing patients on boardThe need for patient database and effective communicationEmerging technologies, digitization and social platformBenefits of digital technology and regulatory hurdles17:20 – Chairperson’s closing remarksFor more information about this conference visit https://www.researchandmarkets.com/r/qlpugxResearch and Markets also offers Custom Research services providing focused, comprehensive and tailored research.CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900